Table 3: Alterations of plasma ASP and other parameters after improvement of insulin resistance with PPAR treatment

		Pre-study	Post-study	% altration
Hemoglobin A1c (NGSP^b)	[%]	6.6±0.8	6.5±0.9	98.5
Immuno reactive insulin (IRI)		15.7±13.1	8.5±6.4	54.1
HOMA-IR^c		6.5±7.4	2.8±2.2^a	43.1
Triglyceride (TG)	[mg/dL]	139±61	123±64^a	88.5
Low density liprotein-cholesterol (LDL-C)	[mg/dL]	121±35	114±21^a	94.2
Adiponectin (ADN)	[μg/mL]	4.1±3.6	4.4±3.6	107.3
Tumor necrosis factor α (TNF α)	[pg/mL]	3.1±5.9	2.4±1.0	77.4
C3	[mg/dL]	121±37	101±32^a	83.5
iC3b	[μg/mL]	306±21	254±25^a	83.0
Acylation stimulating protein (ASP)	[μg/mL]	224±36	203±35^a	90.6
Soluble membrane attack complex (sMAC)	[ng/mL]	3.43±0.70	2.91±0.54^a	84.8
Interleukin 6 (IL 6)	[pg/mL]	2.0±1.2	1.6±1.0	80.0
Highly sensitive CRP (HSCRP)	[ng/mL]	3111±857	2653±668^a	85.3
Serum creatinine	[mg/dL]	1.41±0.14	1.36±0.21	96.5
Albumin creatinine ratio (ACR)	[mg/gCr]	695±180	581±154	83.6
eGFR^d	[mL/min]	49.6±24.8	52.4±29.8	105.6

Values are expressed as mean±SD, ^a: statistically significant vs. Pre-study samples, ^b: National glycohemoglobin standardization program, ^c: homeostasis model assessment of insulin resistance, ^d: estimated glomerular filtration rate